Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

QuANTUM-First Study Group

Research output: Contribution to journalArticlepeer-review

57 Scopus citations

Fingerprint

Dive into the research topics of 'Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences